Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.65 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | BLM | P54132 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desglymidodrine SCHEMBL29822558 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| Desglymidodrine SCHEMBL6031919 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| Desglymidodrine SCHEMBL29583490 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| Desglymidodrine SCHEMBL6032882 | 1.00 | ADRA1A (1.00) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| Desglymidodrine SCHEMBL6576723 | 0.98 | ADRA1A (0.97) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| SCHEMBL7623821 | 0.88 | ADRA1A (0.79) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL7767510 | 0.87 | ADRA1A (0.77) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| SCHEMBL7153263 | 0.86 | ADRA1A (0.75) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| SCHEMBL29825075 | 0.86 | ADRA1A (0.75) | ADRA1AADRA2ALMNACYP1A2TSHR | |
| SCHEMBL10086096 | 0.86 | ADRA1A (0.75) | ADRA1AADRA2ALMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115745812-A | Preparation method of 2-amino-1- (2,5-dimethoxyphenyl) ethanol | 成都沣德煜晟医药科技有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-20220144754-A1 | PROCESS FOR PREPARATION OF MIDODRINE AND INTERMEDIATES THEREOF | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-05-12 | — | — | US | claimed |
| US-20120171274-A1 | TRANSDERMAL PATCH | UDAGAWA HIROKO (JP) | 2012-07-05 | — | — | US | claimed |
| US-20120114738-A1 | TRANSDERMAL PATCH | KOMODA TOSHIKAZU (JP) | 2012-05-10 | — | — | US | claimed |
| EP-2062575-B1 | ADHESIVE PREPARATION COMPRISING DESGLYMIDODRINE | SEKISUI CHEMICAL CO LTD (JP) | 2012-02-15 | — | — | EP | claimed |
| EP-2062576-B1 | ADHESIVE PREPARATION COMPRISING DESGLYMIDODRINE | SEKISUI CHEMICAL CO LTD (JP) | 2012-02-01 | — | — | EP | claimed |
| US-7964213-B2 | For percutaneous administration of a drug other than 2-amino-1-(2',5'- dimethoxyphenyl)ethanol or its salt | NITTO DENKO CORPORATION (JP) | 2011-06-21 | — | — | US | claimed |
| US-20090317452-A1 | Transdermal patch | SEKISUI CHEMICAL CO. TD. | 2009-12-24 | — | — | US | claimed |
| US-20090258063-A1 | Transdermal patch | SEKISUI CHEMICAL CO., LTD. | 2009-10-15 | — | — | US | claimed |
| EP-2062576-A1 | ADHESIVE PREPARATION | Sekisui Chemical Co., Ltd. (JP) | 2009-05-27 | — | — | EP | claimed |
| CN-1422150-A | Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine | NYCOMED DANMARK AS (AT) | 2003-06-04 | — | — | CN | claimed |
| EP-1289493-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DESGLYMIDODRINE AS AN ACTIVE DRUG SUBSTANCE | Nycomed Austria GmbH (AT) | 2003-03-12 | — | — | EP | claimed |
| EP-1282406-A1 | PHARMACEUTICAL KIT COMPRISING MIDODRINE AS AN ACTIVE DRUG SUBSTANCE | Nycomed Austria GmbH (AT) | 2003-02-12 | — | — | EP | claimed |
| EP-1267841-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MIDODRINE AND/OR DESGLYMIDODRINE | Nycomed Austria GmbH (AT) | 2003-01-02 | — | — | EP | claimed |
| US-20020193445-A1 | Pharmaceutical kit comprising midodrine as active drug substance | NYCOMED AUSTRIA GMBH (AT) | 2002-12-19 | — | — | US | claimed |
| US-20020147232-A1 | Pharmaceutical compositions comprising desglymidodrine as an active drug substance | NYCOMED DANMARK A/S (DK) | 2002-10-10 | — | — | US | claimed |
| US-20020034544-A1 | Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine | NYCOMED AUSTRIA GMBH (AT) | 2002-03-21 | — | — | US | claimed |
| WO-2001089473-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING DESGLYMIDODRINE AS AN ACTIVE DRUG SUBSTANCE | NYCOMED AUSTRIA GMBH (AT) | 2001-11-29 | — | — | WO | claimed |
| WO-2001074334-A1 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION CONTAINING MIDODRINE AND/OR DESGLYMIDODRINE | NYCOMED AUSTRIA GMBH (AT) | 2001-10-11 | — | — | WO | claimed |
| WO-2001074335-A1 | PHARMACEUTICAL KIT COMPRISING MIDODRINE AS AN ACTIVE DRUG SUBSTANCE | NYCOMED AUSTRIA GMBH (AT) | 2001-10-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144754-A1 | PROCESS FOR PREPARATION OF MIDODRINE AND INTERMEDIATES THEREOF | POR, QDPR, CYP3A7 | ADRA1A 187/4885ADRA2A 301/4885LMNA 3165/4885 |
| US-20020034544-A1 | Controlled release pharmaceutical composition for oral use containing midodrine and/or active metabolite, desglymidodrine | REN, SI, PDE9A | ADRA1A 67/4885ADRA2A 93/4885LMNA 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.